Application of lymphocyte apheresis combined with plasma exchange in the treatment of advanced hepatitis B associated liver failure

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100044671

Enrollment

Unknown

Registered

2021-03-25

Start date

2021-04-01

Completion date

Unknown

Last updated

2021-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Failure

Interventions

experimental group:Lymphocyte apheresis combined with plasma exchange

control group:plasmapheresis

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Aged between 18 and 60 years; (2) HBsAg (+) more than half a year; (3) TBil increased > 17umol/L/ day (more than three days); (4) 20% = 400U/L or AST >= 400U/L; (6) Signed the informed consent.

Exclusion criteria

Exclusion criteria: (1) Liver lesions with other causes, such as drugs, alcohol, other viral hepatitis, etc; (2) Complicated with malignant tumor; (3) Complicated with hepatic encephalopathy, hepatorenal syndrome and severe infection; (4) The circulatory system is unstable; (5) Patients with active bleeding.

Design outcomes

Primary

Measure	Time frame
Model for end-stage liver disease (MELD) score;The clinical improvement rate was at 4 weeks;Total bilirubin;International standardized ratio(INR);	—

Secondary

Measure	Time frame
12-week survival;	—

Countries

China

Contacts

Public ContactGao Hongbo

Guangzhou Eighth People's Hospital, Guangzhou Medical University

gz8hghb@126.com+86 20-83710427

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026